Clinical Trials on Hypertension, Dyslipidemia

Total 13360 results

GlaxoSmithKline

Completed

GW501516 In Subjects Who Have Low Level Of High-Density Lipoprotein Cholesterol

Dyslipidaemia | Dyslipidaemias

Germany, Estonia, Belgium, France, Netherlands, Denmark, Portugal, Norway, Sweden, Lithuania, Finland
GlaxoSmithKline

Completed

Study To Evaluate The Effects Of GW856553 On Endothelial Function/Vascular Compliance In Subjects With Dyslipidaemia.

Healthy Subjects | Dyslipidaemia | Dyslipidaemias

United Kingdom
Xention Ltd

Completed

Study of the Electrocardiographic Effects of TA-8995

Dyslipidaemia

United Kingdom
AstraZeneca

Completed

Statin Therapy Results in the Real World Practice in the Czech Republic (STEP)

Dyslipidaemia

Czech Republic
AstraZeneca

Completed

A Study of AZD8233 in Participants With Dyslipidemia

Dyslipidaemia

Denmark, United States, Slovakia
Novartis Pharmaceuticals

Completed

Safety and Pharmacokinetis of TAP311 in Dyslipidemic Patients

Dyslipidaemia

Jordan, United States, Taiwan
AstraZeneca

Completed

48-wk Open Label Phase IIIb to Evaluate Efficacy and Safety

Dyslipidaemia
Boryung Pharmaceutical Co., Ltd

Completed

A Randomized, Double-blind, Multicenter, Phase III Study to Evaluate the Efficacy and Safety of Combination of Fimasartan/Rosuvastatin in Comparison to Each Component Administered Alone in Patients With Essential Hypertension and Dyslipidemia

Essential Hypertension, Dyslipidemia

Korea, Republic of
Boryung Pharmaceutical Co., Ltd

Completed

A Study to Evaluate the Efficacy and Safety of Combination Treatment of Fimasartan/Atorvastatin in Patients With Essential Hypertension and Dyslipidemia (FIESTA)

Essential Hypertension, Dyslipidemia

Korea, Republic of
Daewoong Pharmaceutical Co. LTD.

Unknown

Clinical Trail to Evaluate the Efficacy and Safety of DWJ1451

Hypertension, Dyslipidemia

Korea, Republic of
GlaxoSmithKline

Completed

A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Administering Multiple Oral Doses of GSK1292263 Alone and With Atorvastatin

Dyslipidemias | Dyslipidaemias

United States
GlaxoSmithKline

Completed

Dyslipidemia Study Investigating The Increase In "Good Cholesterol"

Dyslipidaemias

United States, Canada
GlaxoSmithKline

Completed

A Study in Healthy Volunteers of Single Doses of Orally Administered Investigational Product to Investigate Safety, Tolerability, and Pharmacokinecs.

Dyslipidaemias

United States
Jeil Pharmaceutical Co., Ltd.

Completed

Study to Evaluate the Efficacy and Safety of Telmisartan/Amlodipine/Rosuvastatin

Dyslipidemia With Hypertension

Korea, Republic of
Novo Nordisk A/S

Recruiting

A Study to Look at How Safe a New Medicine (NNC0491-6075) is in Healthy People and in Participants With High Levels of Fat in the Blood

Healthy Volunteers | Dyslipidaemia

United States
AstraZeneca

Completed

Centralized Pan-Russian Survey on the Undertreatment of Hypercholesterolemia (CEPHEUS)

Dyslipidaemia

Russian Federation
AstraZeneca

Completed

Treatment of Hypercholesterolaemia in South Asian Subjects (IRIS) (IRIS)

Hypercholesterolemia | Dyslipidaemia
Boryung Pharmaceutical Co., Ltd

Completed

A Combination Drug Including Fimasartan and Statins in Patients With Hypertension and Dyslipidemia (FIMASTAR)

Hypertension and Dyslipidemia

Korea, Republic of
AstraZeneca

Completed

Treatment of Hypercholesterolaemia in Hispanic Subjects (STARSHIP) (STARSHIP)

Hypercholesterolemia | Dyslipidaemia
IlDong Pharmaceutical Co Ltd

Not yet recruiting

A Post-marketing Surveillance to Assess Safety and Efficacy of Telostop Plus Tab.

Hypertension, Dyslipidemia
GlaxoSmithKline

Completed

Study to Test GSK256073 in Patients With Dyslipidemia

Dyslipidemias | Dyslipidaemias

United States
GlaxoSmithKline

Completed

Repeat Dose Food Effect Study of GSK256073F in Healthy Adult Subjects

Dyslipidaemias

United States
AstraZeneca

Completed

CEntralized Pan-Russian Survey of tHE Undertreatment of hypercholeSterolemia II (CEPHEUS II) (CEPHEUSII)

Dyslipidaemia

Russian Federation
Xention Ltd

Completed

Bioequivalence Study of Capsule and Tablet Formulations of TA-8995

Dyslipidaemia

United Kingdom
AstraZeneca

Completed

Rosuvastatin Versus Atorvastatin in the Treatment of Hypercholesterolaemia in African American Subjects(ARIES) (ARIES)

Hypercholesterolemia | Dyslipidaemia
Chong Kun Dang Pharmaceutical

Completed

Clinical Trial to Evaluate the Efficacy and Safety of CKD-386

Dyslipidemia Patients With Hypertension

Korea, Republic of
Chong Kun Dang Pharmaceutical

Completed

Clinical Study to Evaluate the Pharmacokinetic Profiles and Safety of CKD-386 in Healthy Volunteers Under Fasting Conditions

Hypertension and Dyslipidemia

Korea, Republic of
Chong Kun Dang Pharmaceutical

Completed

Clinical Trial to Evaluate the Efficacy and Safety of CKD-333 Tablet

Hypertensive Patients With Dyslipidemia

Korea, Republic of
Daewon Pharmaceutical Co., Ltd.

Completed

Study of Multiple Oral Dosing to Evaluate the Safety and the Pharmacokinetic Drug-drug Interaction of Telmisartan/Amlodipine and Rosuvastatin in Healthy Male Volunteers

Hypertension and Dyslipidemia
Chong Kun Dang Pharmaceutical

Completed

A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-348(5)

Hypertension and Dyslipidemia

Korea, Republic of
Chong Kun Dang Pharmaceutical

Completed

Clinical Trial to Evaluate the Tolerability and the Pharmacokinetics of CKD-348

Hypertension and Dyslipidemia

Korea, Republic of
GlaxoSmithKline

Completed

A Second Study to Determine the Effect of GSK256073A on HVTs

Healthy Subjects | Dyslipidaemias

United States
Yuhan Corporation

Completed

PK Study of Telmisartan/Rosuvastatin FDC Compared to Combination of Telmisartan and Rosuvastatin

Dyslipidemia & Hypertension

Korea, Republic of
GlaxoSmithKline

Completed

Study Of Pharmacokinetics and Pharmacodynamics Effects Of GSK256073A On Healthy Volunteers

Healthy Subjects | Dyslipidaemias

United States
Chong Kun Dang Pharmaceutical

Completed

A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-348 (CKD-348)

Hypertension and Dyslipidemia

Korea, Republic of
Chong Kun Dang Pharmaceutical

Completed

A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-386(2)

Hypertension and Dyslipidemia

Korea, Republic of
Chong Kun Dang Pharmaceutical

Completed

A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-386

Hypertension and Dyslipidemia

Korea, Republic of
Jeil Pharmaceutical Co., Ltd.

Completed

The PK Characteristics of the Co-administration of Rosuvastatin and Telmisartan/Amlodipine and JLP-1401 in Healthy Male Volunteers Volunteers

Hypertension With Dyslipidemia

Korea, Republic of
Chong Kun Dang Pharmaceutical

Completed

A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-348(2)

Hypertension and Dyslipidemia

Korea, Republic of
Chong Kun Dang Pharmaceutical

Completed

Study to Evaluate the Safety and Pharmacokinetics of CKD-331

Hypertension and Dyslipidemia

Korea, Republic of
Chong Kun Dang Pharmaceutical

Completed

A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-348(3)

Hypertension and Dyslipidemia

Korea, Republic of
Chong Kun Dang Pharmaceutical

Completed

A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-386(2) 80/20/10mg

Hypertension and Dyslipidemia

Korea, Republic of
Chong Kun Dang Pharmaceutical

Completed

A Clinical Trial to Evaluate the Pharmacokinetics and Tolerability of CKD-348

Hypertension and Dyslipidemia

Korea, Republic of
Chong Kun Dang Pharmaceutical

Completed

A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-386(5) 80/20/10mg

Hypertension and Dyslipidemia

Korea, Republic of
Chong Kun Dang Pharmaceutical

Completed

A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-386(3) 80/20/10mg

Hypertension and Dyslipidemia

Korea, Republic of
Jeil Pharmaceutical Co., Ltd.

Completed

The PK Characteristics of the Co-administration of Rosuvastatin and Telmisartan/Amlodipine and JLP-1401 in Healthy Adult Volunteers Volunteers

Hypertension With Dyslipidemia

Korea, Republic of
AstraZeneca

Completed

IIIb 6 Week Open Label Multicentre Rosuvastatin & Simvastatin

Fredrickson Type IIa & Type IIb Dyslipidaemia
NeuroBo Pharmaceuticals Inc.

Completed

A 12-Week Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia (INDIGO-1)

Severe Hypertriglyceridemia | Mixed Dyslipidaemia

United States, Canada
Pfizer's Upjohn has merged with Mylan to form Viatris...

Completed

Clinical Utility of Caduet in Achieving Blood Pressure and Lipid Endpoints in a Specific Patient Population (CAPABLE)

Hypertension | Dyslipidemia

United States
Pfizer's Upjohn has merged with Mylan to form Viatris...

Completed

Caduet in an Untreated Subject Population (CUSP)

Hypertension | Dyslipidemia

United States

3

Subscribe